Abstract
Metastatic triple-negative breast cancer (mTNBC) patients tend to have a poor overall survival. The primary goals of treatment focus on palliation of symptoms and improvement in overall survival (OS). Single-agent sequential chemotherapy with anthracycline or taxane has remained the cornerstone of treatment for many years. The FDA has approved newer agents such as poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors upfront in germline BRCA (gBRCA) 1/2 mutation carriers; atezolizumab and nab-paclitaxel combination frontline in patients with PD-L1 expression > 1%; and sacituzumab govitecan (IMMU-132), an antibody-drug conjugate in heavily pretreated mTNBC patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1793-1796 |
Number of pages | 4 |
Journal | Breast Journal |
Volume | 26 |
Issue number | 9 |
Early online date | Jun 23 2020 |
DOIs | |
State | Published - Sep 2020 |
Keywords
- PARP inhibitors
- TNBC
- advances
- immunotherapy
- metastatic
ASJC Scopus subject areas
- Internal Medicine
- Surgery
- Oncology